Shanghai Pharmaceutical Machinery Co., Ltd (SPM) specialized in designing and manufacturing pharmaceutical machinery. We have strong technical power and absorbed the technical essence from abroad constantly. With the cooperation of the research institute and design institute, SPM offers newly generated machinery products, which fully comply with GMP requirements. We continue to promote quality systems for global customers and strengthen our core competitiveness to move forward in serving the pharmaceutical industry.

We are a comprehensive machinery manufacturer and supplier, focusing on pharmaceutical, food and cosmetic machinery's R&D, manufacturing and marketing, providing professional pharmaceutical solid dosage equipment, liquid dosage equipments, packaging machinery and so on. We insist on consumers' pursuit of high-quality life, Insights from global experts on innovations, trends, and sustainability to empower your productive decisions, supply cost-effective solutions.

Shanghai Ritai Medicine Equipment Project Co., Ltd., mainly specializes in innovation and development of Fermentor, Fermentation System, Bioreactor, CIP Station, Solution Preparation System, Process Module, sanitary stainless steel pressure vessels, atmospheric pressure vessels, valves and piping system which are widely used in the following fields, such as pharmaceutical, chemical, biological, cosmetic and food industry.

Located in Shanghai China, we have been specialized in manufacturing tablet press machines for more than 32 years. Die & punch sets for different brands of tablet press machines, such as EU or IPT D/B/BB/BBS tooling, can be customized here in our factory.

ShengDin Pharmaceutical Machinery Equipment Co.,Ltd is under Shanghai Sheng Guan group, it is manufacturr company of Shanghai Shengguan company,it is located in Jiaxing City Zhejiang province.We are the company which devotes to research and development of pharmaceutical machinery and packaging equipment, which integrates both sales and after sales-services in one enterprise. We are a member of China Pharmaceutical Equipment Industry Association. We employ experienced experts and professors of Shanghai Light Industry Design Institute to design and develop our products. We introduce advanced technology and constantly improve our products. We product professional injection, oral liquid syrup, eye drops, sprays, vaccines and other liquid filling production line, powder filling production line, tablets filling production line, and various types of stand-alone machines. The products are sold throughout the countries and exported to America, Europe, Asia, the middle East, and other parts of the world. We provide free maintenance service during the period of warranty and the service of lifelong maintenance also Our sales service gets a high reputation from customers . Our company is passed ISO9001 quality system certification, some products are passed CE. Our company puts the “ treat everyone with a sincere heart, base in honesty, win with excellent” business philosophy into practice. We look forward to cooperating with you with the best prices, excellent quality and service.

JYMed Technology Co., Ltd. (hereinafter referred to as "JYMed Peptide") was founded in 2009, specializing in peptide development and manufacturing. The company has over 600 employees, including 130+ scientists, a 7,000㎡ GLP-compliant research laboratory, and an FDA cGMP-compliant API manufacturing facility. With an annual production capacity set to exceed 10 tons by 2026, JYMed Peptide leverages over 16 years of focused experience in peptide development and mass production to provide seamless, end-to-end solutions—from custom synthesis to full commercialization.

"Shijiazhuang No.4 Pharmaceutical Co., Ltd.(SJZ No.4 Pharmaceutical), founded in 1948, is a large-scale high-tech pharmaceutical enterprise integrating R&D, production, and global sales. As a listed company on the Hong Kong Main Board, it has firmly established itself as a leader in China's pharmaceutical industry, ranking among the Top 100 Pharmaceutical Enterprises and honored as one of China's Excellent Export-Oriented Brands in the chemical pharmaceutical preparation industry, boasting a high reputation in both domestic and international markets. Export business has always been a core development pillar of SJZ No.4 Pharmaceutical, with its products reaching more than 100 countries and regions across five continents, including Africa, Southeast Asia, Europe and Latin America. The company has maintained a double-digit annual growth rate in export volume for years, ranking the forefront in the domestic pharmaceutical export industry, especially in the large-volume infusion sector, where it has become a leading exporter in China. Its export product portfolio is increasingly diversified, initially focusing on high-quality infusion solutions and now expanding to oral preparations, small-volume injections, APIs and other categories. Its specialty API caffeine, a core export product, is highly recognized globally for its high purity and traceability, with the company being one of the world's major caffeine suppliers, whose products are sold to over 60 countries and regions. To ensure the international competitiveness of its export products, SJZ No.4 Pharmaceutical has always adhered to strict quality control and international certification standards. The company has built modern production workshops and automated logistics centers in accordance with EU GMP standards, and its production lines for infusion solutions and other preparations have realized full automation and informatization, reaching the international advanced level. Up to now, the company has obtained 435 product registration certificates in 19 countries including the United Arab Emirates and Costa Rica, and has passed official audits and quality certifications of more than 10 countries such as the Philippines and Peru. In 2025, its caffeine API successfully obtained the EU CEP certification, and its subsidiary Guangxiang Pharmaceutical obtained the carbon footprint report certification in 2024, laying a solid foundation for the company's products to enter the high-standard international markets such as Europe. The company's commitment to green production and low-carbon development has also become a key advantage in its international cooperation, winning wide recognition from global partners. SJZ No.4 Pharmaceutical has formed a complete industrial chain layout from specialty APIs and new preparations to pharmaceutical packaging materials R&D, production and application, with its subsidiary Jiangsu Bosheng Medical New Materials focusing on pharmaceutical packaging R&D, and Hebei Guangxiang Pharmaceutical being an important base for API production. This integrated industrial chain not only ensures the stability of the company's raw material supply and product quality, but also reduces production costs, enhancing the cost advantage of its export products. Looking forward, SJZ No.4 Pharmaceutical will continue to adhere to the dual-wheel drive of innovation and international cooperation, increase R&D investment in high-end preparations and innovative drugs, further expand its international certification scope and market coverage, and strive to realize the leap from ""scale export"" to ""value export"". With high-quality products and professional services, the company is committed to becoming a world-renowned pharmaceutical enterprise, making more high-quality Chinese pharmaceutical products go global, and contributing to the global medical and health cause."

**Shilpa Medicare Ltd.** is a global pharmaceutical company headquartered in Hyderabad, India. Founded in 1987, the company is primarily engaged in the development, manufacturing, and marketing of generic pharmaceutical products, active pharmaceutical ingredients (APIs), and biosimilars. Shilpa Medicare focuses on a wide range of therapeutic areas, including oncology, cardiology, neurology, and other specialized treatments. The company has a strong presence in both the domestic and international markets, exporting its products to over 100 countries. With a commitment to quality and innovation, Shilpa Medicare invests heavily in research and development (R&D), striving to develop cost-effective solutions that improve patient outcomes. It has state-of-the-art manufacturing facilities that adhere to international regulatory standards, including those of the U.S. FDA, EU, and WHO-GMP. Shilpa Medicare is known for its focus on biosimilars, with a robust pipeline of biosimilar products for various cancers and autoimmune diseases. Its efforts in cutting-edge research and manufacturing excellence have positioned it as a leading player in the global pharmaceutical industry.

Kelun Pharmaceutical, as a leading enterprise in China's pharmaceutical industry, offers a broad and technologically advanced product portfolio. In the field of intravenous therapies, the company has achieved a major breakthrough in safe infusion technology with its self-developed KeLiBag® (the domestically and internationally first upright soft-bag infusion) and ready-to-use high-end infusions (such as total parenteral nutrition multi-chamber bags and antibiotic premixed dual-chamber bags). The products feature high safety, cost-effectiveness, and environmental advantages, and are widely used in emergency medical settings and exported to more than 50 countries and regions. In the antibiotic sector, through its subsidiary Chuanning Biotech, Kelun has built a complete value chain—from intermediates to active pharmaceutical ingredients (APIs) to formulations—overcoming the challenges of "three wastes" governance and becoming a green environmental benchmark. In innovative medicines, Kelun Botai focuses on antibody–drug conjugate (ADC) development. Its TROP2 ADC, Jaitelai®, and PD-L1 monoclonal antibody Ketailai® have been approved for market, providing new options for tumor treatment. The company has also reached a multi-billion-dollar licensing collaboration with Merck & Co, establishing international leadership in innovation. Moreover, the company is expanding into the anti-aging arena, developing various nutraceutical ingredients and forming a full-chain product matrix.